Xbrane Biopharma Q4 2022: Just ahead of launch

Research Update



Redeye slightly adjusts its fair value range of Xbrane on the back of the Q4 report. Considering the significant valuation discount compared to peer biosimilar developers and a year containing high-impact catalysts, we see good prospects for an upside opportunity.


Filip Einarsson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.